Breast Center, Hebei Medical University Fourth Affiliated Hospital, No. 169 Tianshan Street, Shijiazhuang, 050035, China.
Sci Rep. 2021 May 11;11(1):10034. doi: 10.1038/s41598-021-89475-y.
Early reports indicate that metformin, a clinical drug administered to treat type 2 diabetes mellitus (T2DM), was found to be associated with a better prognosis of cancer. The objective of this study was retrospectively analyzed the effect of metformin on the outcomes of Chinese breast cancer patients with T2DM. A total of 3757 primary invasive breast cancer patients who underwent surgery from January 2010 to December 2013 were enrolled. According to the medication treatment, all the patients were divided as non-diabetes group, metformin group and insulin group. The follow-up data for disease-free survival (DFS) and overall survival (OS) were obtained from 3553 patients (median follow up of 85 months) and estimated with the Kaplan-Meier method followed by a log-rank test. Multivariate Cox proportional hazards regression model was applied. The results showed that there was a significant survival difference among non-diabetes group, metformin group and insulin group, 5-year DFS was 85.8%, 96.1%, 73.0%, and 5-year OS was 87.3%, 97.1%, 73.3% respectively (P < 0.05). Prognostic analysis showed metformin was significantly associated with better DFS and OS. Our results suggested that metformin may have a good effect on the survival of invasive breast cancer patients with T2DM.
早期报告表明，二甲双胍是一种用于治疗 2 型糖尿病（T2DM）的临床药物，被发现与癌症的预后更好有关。本研究的目的是回顾性分析二甲双胍对中国 T2DM 乳腺癌患者结局的影响。共纳入 2010 年 1 月至 2013 年 12 月接受手术的 3757 例原发性浸润性乳腺癌患者。根据药物治疗，所有患者分为非糖尿病组、二甲双胍组和胰岛素组。3553 例患者（中位随访 85 个月）获得了无病生存（DFS）和总生存（OS）的随访数据，并采用 Kaplan-Meier 方法进行估计，随后采用对数秩检验。应用多因素 Cox 比例风险回归模型。结果表明，非糖尿病组、二甲双胍组和胰岛素组之间的生存差异有统计学意义，5 年 DFS 分别为 85.8%、96.1%、73.0%，5 年 OS 分别为 87.3%、97.1%、73.3%（P<0.05）。预后分析显示，二甲双胍与更好的 DFS 和 OS 显著相关。我们的结果表明，二甲双胍可能对 T2DM 浸润性乳腺癌患者的生存有良好的影响。
